5 Stocks to Buy with Exponential Growth

4. Prothena Corporation plc (NASDAQ:PRTA)

Average Sales Growth Over the Past 5 Years: 4640%

Prothena Corporation plc (NASDAQ:PRTA) is a late-stage clinical company that is working on treatments for diseases caused by protein dysregulation. Analysts are bullish on Prothena Corporation plc (NASDAQ:PRTA)’s Alzheimer’s pipeline.

In a February earnings call Prothena Corporation plc (NASDAQ:PRTA) talked in detail about its products and pipeline.

“As new data becomes available on the clinical regulatory and commercial landscape in the Alzheimer’s field, we believe our programs are well-positioned to revolutionize the care of patients suffering from this devastating disease. To that end, we can expect the following key milestones in 2023 and 2024. First, preclinical data demonstrating the superior binding characteristics of PRX012 at the upcoming AD/PD 2023 annual meeting. Second, the multiple ascending dose portion of the Phase 1 PRX012 study has commenced, and we are on track to report top line data from the initial cohort by the end of 2023. Third, the Phase 1 multiple ascending dose study for PRX005 is ongoing with top line data expected by year-end 2023, further elucidating the potential of targeting the MTBR tau in treating Alzheimer’s.

Fourth, for PRX123, we are looking forward to submitting an IND by the end of 2023. Fifth, for prasinezumab we expect that Roche will report top line data from the Phase 2b PADOVA study in 2024. Six, in our rare peripheral amyloid portfolio, we continue to …” [read the full earnings call transcript here].

A total of 27 hedge funds out of the 910 hedge funds tracked by Insider Monkey reported owning stakes in Prothena Corporation plc (NASDAQ:PRTA). The most significant stakeholder of Prothena Corporation plc (NASDAQ:PRTA) during this period was Oleg Nodelman’s EcoR1 Capital which owns a $791 million stake in the company.